Y Intercept Hong Kong Ltd Increases Stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Y Intercept Hong Kong Ltd boosted its position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 245.5% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 120,958 shares of the biopharmaceutical company’s stock after acquiring an additional 85,951 shares during the period. Y Intercept Hong Kong Ltd’s holdings in Amicus Therapeutics were worth $1,139,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Wellington Management Group LLP raised its position in shares of Amicus Therapeutics by 13.5% in the third quarter. Wellington Management Group LLP now owns 23,964,044 shares of the biopharmaceutical company’s stock valued at $255,936,000 after purchasing an additional 2,856,101 shares during the period. Point72 Asset Management L.P. bought a new position in Amicus Therapeutics in the 3rd quarter worth approximately $13,530,000. Rice Hall James & Associates LLC grew its stake in Amicus Therapeutics by 41.0% in the 4th quarter. Rice Hall James & Associates LLC now owns 1,371,080 shares of the biopharmaceutical company’s stock valued at $12,916,000 after buying an additional 398,942 shares in the last quarter. Old West Investment Management LLC raised its holdings in Amicus Therapeutics by 617.2% during the 3rd quarter. Old West Investment Management LLC now owns 340,441 shares of the biopharmaceutical company’s stock valued at $3,636,000 after acquiring an additional 292,976 shares during the period. Finally, PDT Partners LLC purchased a new stake in shares of Amicus Therapeutics during the third quarter worth $2,702,000.

Analyst Ratings Changes

Several equities analysts have recently weighed in on FOLD shares. Guggenheim lifted their price target on Amicus Therapeutics from $13.00 to $15.00 and gave the company a “buy” rating in a research report on Thursday, November 7th. JPMorgan Chase & Co. lifted their target price on Amicus Therapeutics from $16.00 to $17.00 and gave the company an “overweight” rating in a report on Tuesday, November 12th. StockNews.com downgraded shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, February 20th. Morgan Stanley reaffirmed an “equal weight” rating and set a $12.00 price objective (down previously from $17.00) on shares of Amicus Therapeutics in a research note on Friday, December 13th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $21.00 target price on shares of Amicus Therapeutics in a report on Wednesday, January 15th. Three equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Amicus Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $16.75.

Insider Activity

In other news, CEO Bradley L. Campbell sold 7,500 shares of the company’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $10.02, for a total value of $75,150.00. Following the completion of the transaction, the chief executive officer now directly owns 886,654 shares in the company, valued at approximately $8,884,273.08. This represents a 0.84 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 2.20% of the company’s stock.

Amicus Therapeutics Trading Down 0.9 %

Shares of FOLD opened at $9.03 on Thursday. Amicus Therapeutics, Inc. has a 1-year low of $8.78 and a 1-year high of $14.02. The company has a market capitalization of $2.77 billion, a P/E ratio of -50.17, a P/E/G ratio of 1.51 and a beta of 0.61. The company has a debt-to-equity ratio of 2.01, a current ratio of 3.39 and a quick ratio of 2.42. The firm’s 50 day simple moving average is $9.52 and its 200 day simple moving average is $10.38.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.